专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090221509A1 Tumour-associated peptides binding to MHC-molecules 审中-公开
标题翻译：与MHC分子结合的肿瘤相关肽
公开(公告)号：US20090221509A1
公开(公告)日：2009-09-03
申请号：US10549718
申请日：2004-03-23
申请人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
发明人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
IPC分类号： A61K38/10 , A61K35/12 , C12N5/10 , C12N15/63 , G01N33/68 , A61K38/08 , C07K7/08 , C07K7/06 , C07H21/00
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
摘要翻译：本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID No。 101，其中肽具有结合人类主要组织相容性复合物（MHC）I类分子的能力。此外，本发明涉及肽和编码肽的核酸用于制备药物以及用于治疗肿瘤疾病和/或腺瘤性疾病的用途。此外，描述了具有至少一种肽的药物组合物。

2. 发明申请

US20080038285A1 Method for Identifying and Quantifying of Tumour-Associated 有权
标题翻译：肿瘤相关鉴定和定量方法
公开(公告)号：US20080038285A1
公开(公告)日：2008-02-14
申请号：US10587876
申请日：2005-01-28
申请人： Claudia Lemmel , Hans-Georg Rammensee
发明人： Claudia Lemmel , Hans-Georg Rammensee
IPC分类号： A61K39/00 , A61K38/08 , A61P35/00 , C07H21/04 , C07K1/00 , C07K7/00 , C12N15/63 , G01N33/53 , G01N33/68
CPC分类号： G01N33/6878 , C07K7/06 , G01N33/57484 , G01N33/6842 , G01N33/6848 , G01N2333/70539 , Y10T436/24
摘要： Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.
摘要翻译：描述了用于鉴定和定量肿瘤相关肽的方法，其中提供了用于获得肽的第一至少两种不同来源（肿瘤和健康组织），并且彼此分开地来自不同来源的肽被化学修饰通过使用相同元素的至少两种不同的稳定同位素以相同的方式。随后，通过色谱法分离肽，并测定肽的氨基酸序列，其中通过使用稳定同位素来测定具有来自不同样品的相同序列的肽的相对量比例化学改性。此外，本发明涉及具有选自SEQ ID NO：1至36的氨基酸序列的肿瘤相关肽，所述氨基酸序列来自所述序列方案，其中所述肽具有与人类主要组织相容性复合体（MHC）I类。此外，本发明涉及肽用于制备药物和治疗肿瘤疾病和/或腺瘤性疾病的用途。此外，描述了包含至少一种肽的药物组合物。

3. 发明申请

US20110117117A1 NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY 有权
标题翻译：新型免疫缺陷病毒免疫缺陷病毒
公开(公告)号：US20110117117A1
公开(公告)日：2011-05-19
申请号：US12915473
申请日：2010-10-29
申请人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
发明人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
IPC分类号： A61K39/00 , C07K14/47 , C07K7/08 , C07K7/06 , C07K19/00 , C07H21/04 , C07H21/02 , A61K35/26 , A61P35/00 , C12N15/63 , C12N5/10 , C12P21/02 , C12N5/0783
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译：本发明涉及用于免疫治疗方法的肽，核酸和细胞。特别地，本发明涉及癌症的免疫治疗。本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。

4. 发明申请

US20100029573A1 Tumor-associated peptides that bind to mhc-molecules 有权
标题翻译：与mhc分子结合的肿瘤相关肽
公开(公告)号：US20100029573A1
公开(公告)日：2010-02-04
申请号：US11596802
申请日：2005-05-24
申请人： Toni Weinschenk , Claudia Lemmel , Hans-Georg Rammensee , Stefan Stevanovic
发明人： Toni Weinschenk , Claudia Lemmel , Hans-Georg Rammensee , Stefan Stevanovic
IPC分类号： A61K38/08 , C07K7/06 , A61P35/00 , C07H21/04 , C12N15/63 , C12N5/10
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
摘要翻译：本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途和/或腺瘤性疾病。此外，描述了包含至少一种肽的药物组合物。

5. 发明申请

US20090148400A1 COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE 有权
标题翻译：肿瘤相关肽和相关抗癌药组合物
公开(公告)号：US20090148400A1
公开(公告)日：2009-06-11
申请号：US12180113
申请日：2008-07-25
申请人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
发明人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
IPC分类号： A61K39/00 , A61K38/08 , A61K38/10 , A61K38/16 , A61P35/00 , A61K38/17 , A61K39/106 , A61K38/19
CPC分类号： A61K39/0011 , A61K38/193 , A61K45/06 , A61K2039/5158 , A61K2039/53 , A61K2039/572 , C07K14/4748 , A61K2300/00
摘要： The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer.
摘要翻译：本发明涉及免疫治疗肽及其在免疫治疗中的用途，特别是癌症的免疫治疗。本发明公开了肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。特别地，本发明的肽的组合物可用于引发针对结肠直肠癌的抗肿瘤免疫应答的疫苗组合物中。

6. 发明申请

US20090136528A1 NOVEL IMMUNOGENIC EPITOPE FOR IMMUNOTHERAPY 有权
标题翻译：新型免疫缺陷病毒免疫治疗
公开(公告)号：US20090136528A1
公开(公告)日：2009-05-28
申请号：US12180045
申请日：2008-07-25
申请人： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver Schoor , Claudia Lemmel
发明人： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver Schoor , Claudia Lemmel
IPC分类号： A61K39/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07H21/00 , C12N15/63 , A61P35/00 , C12N5/00 , C12P21/00 , C12N5/08 , A61K35/12
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译：本发明涉及用于免疫治疗方法的肽，核酸和细胞。特别地，本发明涉及癌症的免疫治疗。本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。

7. 发明授权

US08669230B2 Immunogenic epitopes for immunotherapy 有权
标题翻译：免疫治疗的免疫原性表位
公开(公告)号：US08669230B2
公开(公告)日：2014-03-11
申请号：US12915473
申请日：2010-10-29
申请人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
发明人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
IPC分类号： C07K7/00
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译：本发明涉及用于免疫治疗方法的肽，核酸和细胞。特别地，本发明涉及癌症的免疫治疗。本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。

8. 发明授权

US08080634B2 Immunogenic epitope for immunotherapy 有权
标题翻译：免疫治疗的免疫原性表位
公开(公告)号：US08080634B2
公开(公告)日：2011-12-20
申请号：US12180045
申请日：2008-07-25
申请人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
发明人： Harpreet Singh , Steffen Walter , Toni Weinschenk , Norbert Hilf , Oliver Schoor , Claudia Lemmel
IPC分类号： C07K5/00
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译：本发明涉及用于免疫治疗方法的肽，核酸和细胞。特别地，本发明涉及癌症的免疫治疗。本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。

9. 发明授权

US07811828B2 Method for identifying and quantifying of tumuor-associated 有权
标题翻译：确定和量化肿瘤相关的方法
公开(公告)号：US07811828B2
公开(公告)日：2010-10-12
申请号：US10587876
申请日：2005-01-28
申请人： Claudia Lemmel , Hans-Georg Rammensee
发明人： Claudia Lemmel , Hans-Georg Rammensee
IPC分类号： G01N33/58 , G01N33/53 , G01N33/533
CPC分类号： G01N33/6878 , C07K7/06 , G01N33/57484 , G01N33/6842 , G01N33/6848 , G01N2333/70539 , Y10T436/24
摘要： Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.
摘要翻译：描述了用于鉴定和定量肿瘤相关肽的方法，其中提供了用于获得肽的第一至少两种不同来源（肿瘤和健康组织），并且彼此分开地来自不同来源的肽被化学修饰通过使用相同元素的至少两种不同的稳定同位素以相同的方式。随后，通过色谱法分离肽，并测定肽的氨基酸序列，其中通过使用稳定同位素来测定具有来自不同样品的相同序列的肽的相对量比例化学改性。此外，本发明涉及具有选自SEQ ID NO：1至36的氨基酸序列的肿瘤相关肽，所述氨基酸序列来自所述序列方案，其中所述肽具有与人类主要组织相容性复合体（MHC）I类。此外，本发明涉及肽用于制备药物和治疗肿瘤疾病和/或腺瘤性疾病的用途。此外，描述了包含至少一种肽的药物组合物。

10. 发明授权

US08242239B2 MHC molecule-binding tumor-associated peptides 有权
标题翻译： MHC分子结合肿瘤相关肽
公开(公告)号：US08242239B2
公开(公告)日：2012-08-14
申请号：US12544117
申请日：2009-08-19
申请人： Toni Weinschenk , Claudia Lemmel , Hans-Georg Rammensee , Stefan Stevanovic
发明人： Toni Weinschenk , Claudia Lemmel , Hans-Georg Rammensee , Stefan Stevanovic
IPC分类号： C07K5/00 , A61K39/00
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
摘要翻译：本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途和/或腺瘤性疾病。此外，描述了包含至少一种肽的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式